Mr. Stephen Kilmer reports

PROFOUND MEDICAL ANNOUNCES CHANGES TO COMMERCIAL ORGANIZATION

Ian Heynen will be resigning from his position as senior vice-president of sale and marketing of Profound Medical Corp. to pursue other opportunities, effective Jan. 7, 2019.

"We would like to thank Ian for his contributions to refining and expanding our commercial capabilities, and wish him well in his future endeavours," said Arun Menawat, Profound's chief executive officer. "We expect a seamless transition as Hartmut Warnken, our VP of international sales, will assume overall commercial management responsibility for those jurisdictions where our technologies are currently cleared for marketing -- Europe, where our focus remains on driving clinical adoption of Tulsa-Pro for treating prostate disease and Asia, where we recently initiated the launch of Sonal for the treatment of uterine fibroids. Moving forward, our commercial team will also continue to prepare for the anticipated U.S. launch of Tulsa-Pro in 2019."

We seek Safe Harbor.